Plus Therapeutics (PSTV) Stock Price, News & Analysis

Company Overview

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors. Plus Therapeutics has secured orphan drug and rare pediatric disease designations for select compounds, reflecting its focus on addressing unmet needs in both adult and pediatric oncology. Clinical studies are conducted in collaboration with academic medical centers and contract research organizations across North America.

Headquartered in Austin, Texas, Plus Therapeutics is led by an executive team with extensive experience in radiopharmaceuticals and oncology drug development. The company maintains research, manufacturing and administrative operations in the United States and continues to expand strategic partnerships to advance its targeted radiotherapeutic portfolio.

Key Stats

• Today's Range: $0.44 to $0.47
• 50-Day Range: $0.30 to $0.80
• 52-Week Range: $0.16 to $2.31
• Volume: 5.04 million shs
• Average Volume: 6.27 million shs
• Market Capitalization: $44.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.88
• Consensus Rating: Buy

Plus Therapeutics Stock Analysis - MarketRank™

Plus Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 373rd out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Buy

Consensus Rating

Plus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Plus Therapeutics has a consensus price target of $7.88, representing about 1,660.6% upside from its current price of $0.45.

Amount of Analyst Coverage

Plus Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Plus Therapeutics are expected to grow in the coming year, from ($2.30) to ($1.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Plus Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Plus Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.73% of the float of Plus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Plus Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Plus Therapeutics has recently increased by 49.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Plus Therapeutics does not currently pay a dividend.

Dividend Growth

Plus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.73% of the float of Plus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Plus Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Plus Therapeutics has recently increased by 49.36%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.67

News Sentiment

Plus Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Plus Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 50 people have searched for PSTV on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.

MarketBeat Follows

17 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 55% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Plus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $53,900.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.79% of the stock of Plus Therapeutics is held by insiders.

Percentage Held by Institutions

Only 3.28% of the stock of Plus Therapeutics is held by institutions.

PSTV Stock Analysis - Frequently Asked Questions

How have PSTV shares performed this year?

Plus Therapeutics' stock was trading at $1.15 at the beginning of the year. Since then, PSTV shares have decreased by 61.1% and is now trading at $0.4473.

How were Plus Therapeutics' earnings last quarter?

Plus Therapeutics, Inc. (NASDAQ:PSTV) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.08. The firm earned $1.39 million during the quarter, compared to analysts' expectations of $1.08 million.

When did Plus Therapeutics' stock split?

Plus Therapeutics's stock reverse split on Monday, May 1st 2023.The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Plus Therapeutics' major shareholders?

Top institutional shareholders of Plus Therapeutics include Jane Street Group LLC (0.19%). Insiders that own company stock include Robert P Lenk, Howard Clowes, Greg Petersen, Marc H Hedrick and Andrew John Hugh Macintyr Sims.
View institutional ownership trends.

How do I buy shares of Plus Therapeutics?

Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Plus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Plus Therapeutics investors own include Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PSTV
• CIK: 1095981
• Web: www.plustherapeutics.com
• Phone: 737-255-7194
• Fax: 858-450-4335
• Employees: 20
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Plus Therapeutics: $7.88
• High Price Target: $20.50
• Low Price Target: $3.00
• Potential Upside/Downside: +1,660.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.98 million
• Net Margins: -357.85%
• Pretax Margin: -357.85%
• Return on Equity: N/A
• Return on Assets: -117.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.26
• Quick Ratio: 1.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.52) per share
• Price / Book: -0.29

Miscellaneous

• Outstanding Shares: 99,265,000
• Free Float: 98,481,000
• Market Cap: $44.40 million
• Optionable: Not Optionable
• Beta: 0.66